A Stool DNA-based SDC2 Methylation Test for the Early Detection of Colorectal Cancer

Korábbi kezelés

• Individuals who do not agree to voluntarily sign an informed consent prior to the initiation of screening
• Subjects who have had a positive FIT or fecal occult blood test within the previous 2 weeks
• Subjects who have had a prior history of colorectal resection
• Subjects who have had overt rectal bleeding or melena within the previous 2 weeks
• Subjects who have a family history or a prior history of hereditary CRC or colorectal neoplasm: Lynch syndrome (HNPCC), familial adenomatous polyposis, MUTYH-associated polyposis, Juvenile polyposis syndrome, Peutz-Jeghers syndrome, and serrated polyposis syndrome, etc.
• Subjects who participated in any "interventional" clinical study within the previous 30 days

Más betegség

• Colorectal cancer patients who did not underwent curative treatment
• Subjects who have inflammatory bowel diseases including Crohn's disease, ulcerative colitis or Behcet disease
• Subject has any condition which, in the opinion of the medical staff should preclude participation in the study

Életkor

• Adults aged < 40 years

Egyéb

• Subjects will be excluded from enrolling into the study if any of the following criteria are met:
• Subjects who are not at high-risk (APCS Score ≤ 3.0) of developing CRC
• Subjects who will not undergo colonoscopy screening within 12 months of consent

• Subjects enrolled into the study must meet the following criteria:
• Individuals who agree to voluntarily sign an informed consent prior to the initiation of screening
• Adults aged ≥ 40 years
• Subjects who are at high-risk (Asia Pacific Colorectal Screening (APCS) Score: 4.0~7.0) of developing CRC
• Subjects who are able and willing to undergo colonoscopy screening within 12 months of consent among individuals who reserved a visit in the division of gastroenterology or health check-up.